Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission
Why is the search for effective treatments for multiple sclerosis (MS) more urgent than ever? Genentech, a member of the Roche Group, has announced that its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS). This pivotal Phase III study, FENhance 1, marks a critical milestone in the development of a high-efficacy oral treatment for both RMS and primary progressive multiple sclerosis (PPMS). The results are consistent with the 59% reduction in annualized relapse rate (ARR) observed in the FENhance 2 study.
Why High-Efficacy Oral Treatments Are Crucial for MS Patients
Multiple sclerosis is a chronic disease affecting over 2.9 million people worldwide, with 85% initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Despite the availability of treatments, 30% of patients remain on low-efficacy oral therapy. Fenebrutinib’s potential to become the first high-efficacy oral treatment for both RMS and PPMS addresses a significant unmet need. The profound benefit on relapsing and progressive disease biology could transform the lives of millions of patients, making the development of such treatments an urgent priority.
The Regulatory Clock Is Already Running for MS Treatments
Just as a marathon runner must maintain a steady pace to reach the finish line, Genentech is racing against the regulatory clock to bring fenebrutinib to market. The company plans to submit the totality of data from all three Phase III fenebrutinib studies to regulatory authorities. This includes the FENhance 1 and 2 studies in RMS and the FENtrepid study in PPMS. The consistent and clinically meaningful results across these studies provide strong evidence for fenebrutinib’s efficacy and safety, positioning it as a potential game-changer in the MS treatment landscape.
Genentech’s Fenebrutinib Targets Both Relapsing and Progressive MS
Genentech is advancing a novel approach to MS treatment with fenebrutinib, an oral, brain-penetrant BTK inhibitor. Unlike most current BTK inhibitors, fenebrutinib is non-covalent and reversible, designed to target both B cells and microglia. This dual action helps control acute inflammation and address chronic damage, making it uniquely suited to tackle both relapsing and progressive forms of MS. Dr. Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, stated, “These pivotal results, together with the earlier data, provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for RMS and PPMS.”
Future Outlook
The future of MS treatment is poised to evolve with the potential approval of fenebrutinib. Just as a lighthouse guides ships through treacherous waters, fenebrutinib could illuminate a new path for MS patients, offering hope for a life with fewer relapses and reduced disability progression. Full data from the FENhance 1 and 2 studies will be shared at the American Academy of Neurology (AAN) Annual Meeting in 2026, providing further insights into this promising treatment.
Conclusion
Genentech’s positive Phase III results for fenebrutinib in RMS highlight the company’s commitment to advancing high-efficacy treatments for MS. For the millions of patients living with this chronic disease, this development could mean a significant improvement in their quality of life. How is your healthcare organization preparing to integrate such innovative treatments into patient care? Join the conversation in the comments below.
About Genentech in neuroscience
Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.
Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
About Genentech
Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
Source link: https://www.businesswire.com
